Table 2.
EC50 values of compound 1 and cisplatin against A2780 and A2780cisR cells, incubated in absence and presence of CuCl2 or cimetidine (Cim), recorded after 24 and 72 h incubation.
| EC50 (μM)a | ||||
|---|---|---|---|---|
| 24 h | 72 h | |||
| Compound | A2780 | A2780cisR | A2780 | A2780cisR |
| 1 | 5.8 ± 1.5 | 15 ± 4 | 2.4 ± 0.3 | 11 ± 0.5 |
| 1 + Cim | 6.6 ± 0.3 | 18.2 ± 6.1 | 0.7 ± 0.2** | 8.1 ± 0.5* |
| 1 + CuCl2 | 4.1 ± 0.3 | 6.1 ± 1.9* | 0.2 ± 0.1** | 3.1 ± 1.0** |
| Cisplatin | 26 ± 2 | 103 ± 3 | 2.3 ± 0.5 | 30 ± 1 |
| Cisplatin + Cim | 22.0 ± 2.1 | 91.7 ± 4.2 | 1.0 ± 0.1** | 21.3 ± 1.1** |
| Cisplatin+ CuCl2 | 22.2 ± 1.3 | 51.0 ± 4.9** | 0.5 ± 0.2** | 18.0 ± 0.6** |
a
Data are expressed as mean ± SD (n ≥ 3).
The reported values are the mean ± SD of three independent experiments. For statistical analysis, the two way ANOVA was used.
*
p ≤ 0.05,
**
p ≤ 0.01 indicate the difference is significant when compared to samples treated with the metallodrugs only (control).